Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy
This study has been completed.
Study NCT00329381   Information provided by University of Mississippi Medical Center
First Received: May 23, 2006   Last Updated: June 3, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Asthma
More general conditions related to this trial
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases
Interventions listed in this trial
Xolair
Additional drug interventions recognized in this trial
Omalizumab
More general drug interventions related to this trial
Anti-Allergic Agents
Anti-Asthmatic Agents
Pharmacologic Actions
Respiratory System Agents
Therapeutic Uses
Sponsors listed in this trial
University of Mississippi Medical Center
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services